DelMar Announces VAL-083 Clinical Trials Will Soon Start for Recurrent Ovarian Cancer

DelMar Announces VAL-083 Clinical Trials Will Soon Start for Recurrent Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has approved DelMar Pharmaceuticals’ investigational new drug (IND) application for VAL-083 for the treatment of ovarian cancer. The IND approval allows the company to start clinical development of its lead drug candidate. A Phase 1/2 trial is set to begin patient enrollment in early 2018, depending on the

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *